TOCOTRIENOLS CAN SUPPORT
INDUCTION OF APOPTOSIS
DEGRADATION AND REDUCTION OF c-FLIP LEVELS
CHEMOPREVENTION AND THERAPEUTIC EFFECTS AGAINST CANCERS
Introduction to Pancreatic Cancer and Delta-TocotrienolThe pancreatic cancer is one of the deadliest cancers. The worrisome fact regarding this cancer is that it is very difficult to diagnose because this cancer has no symptoms. If found at the early stages, then the tumor can be removed and the life expectancy can be increased but since the prognosis isn’t easy, cancer spreads quite fast, and hence, the 5-year survival rate is just 9%.
In this study, a novel function of Delta-Tocotrienol in augmenting tumor necrosis factor-related apoptosis-inducing gland (TRAIL) induced apoptosis or programmed cell death in pancreatic cancer cells was demonstrated.
How does the Delta-Tocotrienol fight Pancreatic cancer?It was observed in the study that, when VEDT was combined with TRAIL, it significantly augmented TRAIL-induced apoptosis in the pancreatic cancer cells. Delta-Tocotrienols was also observed to significantly decrease the cellular FLICE inhibitory protein (c-FLIP) levels. It has been observed that the expression of c-FLIP suppresses the apoptosis mechanism induced by the combination of VEDT and TRAIL. Hence, the reduction of c-FLIP expression is very necessary.
Also, it was demonstrated that Delta-Tocotrienol increased c-FLIP degradation and ubiquitination without affecting its transcription. Hence, it can be concluded that Delta-Tocotrienol decreases c-FLIP levels while degrading it.
Reference for the Study in detail:1. https://cancerci.biomedcentral.com/articles/10.1186/s12935-019-0876-0
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. [PubMed] [Google Scholar]
3. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318–348. [PMC free article] [PubMed] [Google Scholar]
4. Tempero MA, Malafa MP, Behrman SW, Benson AB, 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12:1083–1093. [PubMed] [Google Scholar]
5. Ischenko I, Petrenko O, Hayman MJ. Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas. Proc Natl Acad Sci U S A. 2014;111:3466–3471. [PMC free article] [PubMed] [Google Scholar]
6. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114–1117. [PMC free article] [PubMed] [Google Scholar]
7. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol. 2008;26:2806–2812. [PubMed] [Google Scholar]
8. Lee CJ, Li C, Simeone DM. Human pancreatic cancer stem cells: implications for how we treat pancreatic cancer. Transl Oncol. 2008;1:14–18. [PMC free article] [PubMed] [Google Scholar]
9. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030–1037. [PubMed] [Google Scholar]
10. Abel EV, Simeone DM. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology. 2013;144:1241–1248. [PubMed] [Google Scholar]
11. Husain K, Francois RA, Yamauchi T, Perez M, Sebti SM, Malafa MP. Vitamin E delta-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-kappaB activation in pancreatic cancer. Mol Cancer Ther. 2011;10:2363–2372. [PMC free article] [PubMed] [Google Scholar]